
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>MRNA 20231231 Analysis</title>
  <link rel="stylesheet" href="styles.css" />
</head>

<body>
  <header>
    <h1>MRNA 20231231 Analysis</h1>
  </header>

  <nav>
    <ul>
      <li><a href="#business">üöÄ Business Development</a></li>
      <li><a href="#risk">‚öñÔ∏è Risk and Opportunities</a></li>
      <li><a href="#financials">üìä Financials</a></li>
      <li><a href="#recommend">üìà Recommendation</a></li>
    </ul>
  </nav>

  <main>
    <!-- url -->
    <section id="business" class="module">
      <h2>üîé Source Data</h2>
      <p>
        <!-- Your text goes here. -->
        <a href="https://www.sec.gov/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm">source filing at SEC</a>
      </p>
    </section>
  
    <!-- Business Development (text only) -->
    <section id="business" class="module">
      <h2>üöÄ Business Development</h2>
      <p>
        <!-- Your text goes here. -->
        - Incurred $4.7B net loss in 2023 due to COVID-19 vaccine sales decline ($6.1B vs. $18.4B in 2022) as market transitioned to seasonal demand, triggering $2.2B inventory write-downs and $981M manufacturing capacity optimization costs.  <br>- Preparing for 2024 RSV vaccine launch following Phase 3 trials, expanding respiratory portfolio alongside COVID-19 and flu candidates.  <br>- Advanced individualized neoantigen therapy (INT) with Phase 2b data showing 49% reduced recurrence/death risk in melanoma; initiated Phase 3 trials in melanoma and NSCLC.  <br>- Resized global manufacturing footprint in Q3 2023, reducing third-party contract commitments and raw material inventory, incurring $1.5B in write-downs and wind-down costs.  <br>- Increased R&D spend by 47% ($4.8B) to advance 45 pipeline programs, including Phase 3 RSV, CMV, and combination flu/COVID-19 vaccines, and rare disease candidates (PA/MMA).  <br>- Expanded international operations to 19 countries with 5,600 employees, facing challenges in regulatory compliance, foreign currency risks, and geopolitical uncertainties.  <br>- Secured 48% U.S. retail market share for 2023 COVID-19 booster season, up from 37% in 2022, despite overall revenue decline.  <br>- Invested $1.5B in SG&A to build commercial infrastructure for upcoming launches, including digital platforms and global sales teams.  <br>- Faced $3.0B in cancelable purchase obligations for clinical and manufacturing services, reflecting flexible supply chain management amid uncertain demand.  <br>- Maintained $13.3B cash reserves but warned of potential funding needs if pipeline delays occur or commercialization costs exceed projections.
      </p>
    </section>

    <!-- Risk and Opportunities (text only) -->
    <section id="risk" class="module">
      <h2>‚öñÔ∏è Risk and Opportunities</h2>
      <p>
        <!-- Your text goes here. -->
        **Risks:**  <br>- Limited experience with government contracting and regulatory compliance risks potential liability and contract terminations.  <br>- $4.7B net loss in 2023; reliance on COVID-19 vaccine as sole commercial product creates revenue concentration risk.  <br>- Uncertain timelines for new product launches (e.g., RSV vaccine in 2024) and unproven long-term profitability.  <br>- Global operational complexity with 5,600 employees across 19 countries, straining infrastructure and increasing costs.  <br>- Intense competition in mRNA/pharmaceutical markets and potential obsolescence if competitors develop superior products/vaccines.  <br><br>**Opportunities:**  <br>- mRNA platform enables rapid development of vaccines (e.g., COVID-19, RSV, flu) and therapeutic candidates.  <br>- Diversified pipeline of 45 programs, including late-stage candidates for RSV, seasonal flu, and cancer (INT).  <br>- $13.3B cash reserves (as of Dec 2023) support R&D, manufacturing expansion, and strategic investments.  <br>- Planned 2024 RSV launch and combination respiratory vaccines (e.g., COVID-19 + flu) to capture new markets.  <br>- Partnerships for global manufacturing/distribution and advancements in rare disease/personalized cancer therapies.
      </p>
    </section>

    <!-- Financials (with 4 image cards + 5 horizontal sections of text) -->
    <section id="financials" class="module">
      <h2>üìä Financials</h2>

      <!-- Four cards with images (responsive layout) -->
      <div class="card-container">
        <div class="card">
          <img src="MRNA_20231231_1.jpg" alt="Financial Chart 1" />
        </div>
        <div class="card">
          <img src="MRNA_20231231_2.jpg" alt="Financial Chart 2" />
        </div>
        <div class="card">
          <img src="MRNA_20231231_3.jpg" alt="Financial Chart 3" />
        </div>
        <div class="card">
          <img src="MRNA_20231231_4.jpg" alt="Financial Chart 4" />
        </div>
      </div>

      <!-- 5 horizontal sections (each a text paragraph) -->
      <section class="horizontal-section" id="key-items">
        <h3>Key Items</h3>
        <p>
          <!-- Your text goes here. -->
          - Cost of Sales increased from 28.1% to 68.6% of total revenue (+40.5 percentage points).  <br>- Gross Profit decreased from 71.9% to 31.5% of total revenue (-40.4 percentage points).  <br>- Total Operating Expenses rose from 51.1% to 161.8% of total revenue (+110.7 percentage points).  <br>- (Loss) from Operations swung from 48.9% to -61.9% of total revenue (-110.8 percentage point change).  <br>- Interest Income increased from 1.0% to 6.1% of total revenue (+5.1 percentage points).  <br>- Provision for Taxes increased from 6.3% to 11.3% of total revenue (+5.0 percentage points).  <br>- (Loss) before Taxes swung from 49.7% to -57.6% of total revenue (-107.3 percentage point change).  <br>- Net (Loss) swung from 43.4% to -68.8% of total revenue (-112.2 percentage point change).  <br>- Total Revenue decreased by 64.6% year-over-year.  <br>- Gross Profit fell by 84.5% year-over-year.  <br>- Income from Operations declined by 144.9% year-over-year.  <br>- Net Income decreased by 156.4% year-over-year.  <br>- Non-current investments decreased from 32.1% to 25.4% of total assets (-6.7 percentage points).  <br>- Accrued liabilities increased from 31.1% to 39.4% of total liabilities & equity (+8.3 percentage points).  <br>- Deferred revenue (current) decreased from 30.2% to 12.5% of total liabilities & equity (-17.7 percentage points).  <br>- Total current liabilities decreased from 72.8% to 66.1% of total liabilities & equity (-6.7 percentage points).  <br>- Deferred revenue (non-current) decreased from 9.9% to 1.8% of total liabilities & equity (-8.1 percentage points).  <br>- Operating lease liabilities (non-current) increased from 1.4% to 14.1% of total liabilities & equity (+12.7 percentage points).  <br>- Total assets decreased by 28.7% year-over-year.  <br>- Total liabilities decreased by 32.1% year-over-year.  <br>- Total stockholders' equity decreased by 27.5% year-over-year.
        </p>
      </section>

      <section class="horizontal-section" id="profitability-analysis">
        <h3>Profitability Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Net profit margin fell from 43.4% (2022) to -68.9% (2023) due to COVID-19 vaccine market transitioning to seasonal demand, lower sales volume, higher costs, and inventory write-offs.  <br>- Operating profit margin dropped from 48.9% to -61.9% as operational inefficiencies and increased R&D/manufacturing expenses strained profitability.  <br>- ROA declined from 32.3% to -25.6% and ROE from 43.7% to -34.0%, reflecting poor asset utilization and reduced returns exacerbated by shifting market conditions.  <br>- Gross profit margin decreased sharply from 71.9% to 31.5%, driven by higher cost of sales and reduced pricing power amid lower vaccine demand.  <br>- R&D expenses surged to 70.7% of revenue (vs. 17.1% in 2022) from heavy investment in RSV/CMV clinical trials and manufacturing capabilities, prioritizing long-term growth over short-term profitability.  <br>- Strategic manufacturing adjustments, including capacity scaling and inventory write-offs, incurred near-term costs but aimed to align operations with reduced seasonal demand.  <br>- Operational challenges included inefficient resource allocation and higher expenses during market transition, worsening profitability metrics despite cost optimization efforts.
        </p>
      </section>

      <section class="horizontal-section" id="liquidity-analysis">
        <h3>Liquidity Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Current ratio increased from 2.73 (2022) to 3.425 (2023), driven by a larger reduction in current liabilities ($4,923M to $3,015M) than current assets ($13,431M to $10,325M), enhancing short-term liquidity.  <br>- Quick ratio rose from 2.29 to 3.15, reflecting improved ability to meet obligations with liquid assets (excluding inventory/prepaid expenses).  <br>- Cash ratio improved from 2.01 to 2.855, demonstrating stronger coverage of short-term liabilities with cash/cash equivalents.  <br>- Liquidity strengthened despite a $4,714M net loss in 2023, indicating effective liability management and financial resilience.  <br>- All liquidity metrics (current, quick, cash ratios) increased year-over-year, signaling enhanced short-term financial stability and operational flexibility.  <br>- Decreased current liabilities (-39%) outpaced current asset reductions (-23%), directly boosting liquidity ratios.
        </p>
      </section>

      <section class="horizontal-section" id="solvency-analysis">
        <h3>Solvency Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Debt-to-Equity ratio improved from 0.35 (2022) to 0.33 (2023) due to lower total liabilities ($6,735M to $4,572M), but equity fell sharply from $19,123M to $13,854M from a $4,714M net loss and $1,153M stock repurchases.  <br>- Interest coverage ratio plummeted from 217.22x to 35.19x as EBIT declined (net sales dropped from $18,435M to $6,671M) and interest expenses rose, reflecting reduced COVID-19 vaccine demand.  <br>- Solvency ratio (total liabilities/equity) marginally improved from 0.35 to 0.33, but equity erosion from losses and buybacks weakened the overall financial position.  <br>- $2.2B inventory write-downs in 2023, primarily from raw materials, and increased reserves for product returns due to lower Spikevax demand, contributed to higher operating expenses.  <br>- Net loss of $4,714M in 2023 and $1,153M in stock buybacks drove a $5,269M equity decline, raising concerns about long-term obligation sustainability.  <br>- Revenue collapse (down 64% YoY) and rising costs strained profitability, with operating expenses remaining elevated despite lower sales volume.
        </p>
      </section>

      <section class="horizontal-section" id="efficiency-analysis">
        <h3>Efficiency Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Cash Conversion Cycle (CCC) improved from 57.3 days (2022) to 22.8 days (2023), driven by faster inventory turnover and extended supplier payment terms despite slower accounts receivable collection.  <br>- Days Sales Outstanding (DSO) increased from 26.2 to 47.5 days, reflecting slower receivable collections due to lower 2023 sales volumes post-pandemic demand peak.  <br>- Days Inventory Outstanding (DIO) decreased from 63.9 to 15.7 days, aided by $2.2B inventory write-downs (obsolete materials/excess stock) and inventory reduction from $949M to $202M through manufacturing resizing.  <br>- Days Payable Outstanding (DPO) extended from 32.8 to 40.4 days, preserving cash by delaying supplier payments.  <br>- Operating cash flow shifted from $4.98B inflow (2022) to $3.1B outflow (2023), impacted by lower net income and working capital adjustments despite CCC efficiency gains.  <br>- Inventory write-downs of $2.2B in 2023 resulted from reduced COVID-19 vaccine demand, leading to strategic inventory management and manufacturing scale-downs.  <br>- Improved CCC efficiency offset higher DSO through combined DIO reduction and DPO extension, enhancing overall cash flow management despite operating cash outflow.
        </p>
      </section>
    </section>

    <!-- Recommendation (text only) -->
    <section id="recommend" class="module">
      <h2>üìà Recommendation: ‚ùå SELL</h2>
      <p>
        <!-- Your text goes here. -->
        Moderna's financial performance in 2023 was significantly impacted by a decline in revenue, primarily due to reduced demand for its COVID-19 vaccine. The company also faced increased operating expenses, particularly in research and development, which strained profitability. Despite strategic investments in R&D for future growth, the current financial strain, coupled with high expenses and reduced revenue, suggests that earnings per share will likely decrease next year unless there are significant improvements in sales or expense management.
      </p>
    </section>
  </main>

  <footer>
    <p>¬© 2025 SnapStock Report</p>
  </footer>
</body>
</html>


